<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01993576</url>
  </required_header>
  <id_info>
    <org_study_id>2013-000100-41</org_study_id>
    <nct_id>NCT01993576</nct_id>
  </id_info>
  <brief_title>ICG Distribution Using NIF Imaging After IV Injection of ICG in Benign and Malignant Breast Cancer Tissue.</brief_title>
  <acronym>EC2075</acronym>
  <official_title>Histological Study of the (Intravenously Injected) ICG Distribution in Tumor Bearing Breasts and in Axillary Pieces of Dissection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if NIF fluoresent imaging is an effctive approch to&#xD;
      detect the margine of the breast tumoral tissue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective:&#xD;
&#xD;
      Definition of the histological distribution (intravascular, extra vascular, in specific&#xD;
      cells) of ICG (pre-operatively intra-venously injected) at the level of tumoral and healthy&#xD;
      tissues of breast cancer patients (and the potential of axillary lymph nodes found&#xD;
      fluorescent).&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      Evaluation of the ability of the fluorescence imaging to determine the tumor volume and, more&#xD;
      specifically, the boundaries of tumor tissues which will be analyzed by the pathologist.&#xD;
&#xD;
      Analysis of the correlation between fluorescence and &quot;margins&quot; as defined operatively as&#xD;
      tumor (microscopically by the pathologist).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study of the evantual difference of indocyanine in mammalian tissue in patients mastocmemezied for breast canrcinoma.</measure>
    <time_frame>10 months</time_frame>
    <description>Detecting of the fluorescence in between benign and malignant tissue by near infra-red imaging with a camera dictated to identify the margin of the tumor, and Histological detection of indocyanine green distribution in tumor bearing breasts and in axillary pieces of dissection and the detection of tumor cells in lymphe nodes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microscopical detection of indocyanine green in breast tissue.</measure>
    <time_frame>10 months.</time_frame>
    <description>Detecting the fluorescence in between benign and malignant tissue by a microscope with a filter for near ifra-red at a good wave length of ICG.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Breast Cancer.</condition>
  <arm_group>
    <arm_group_label>indocyanine green</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indocyanine green is injected intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine Green</intervention_name>
    <description>Intravenous injection of 0.25 mg/kg Indocyanine Green (ICG) before the surgery</description>
    <arm_group_label>indocyanine green</arm_group_label>
    <other_name>ICG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histopathological diagnosis of breast cancer for which a mastectomy with&#xD;
             axillary dissection is planned.&#xD;
&#xD;
          -  Informed Consent signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of breast cancer established by lumpectomy or &quot;macro-biopsy&quot;.&#xD;
&#xD;
          -  Operation after neo-adjuvant chemotherapy,&#xD;
&#xD;
          -  Age less than 18 years.&#xD;
&#xD;
          -  For pre-menopausal women, an operation planned for the second phase of their cycle.&#xD;
&#xD;
          -  Inability to give informed consent.&#xD;
&#xD;
          -  History of allergy or hypersensitivity to the investigational product, iodine.&#xD;
&#xD;
          -  Clinical or biological hyperthyroidism.&#xD;
&#xD;
          -  Known &quot;toxic&quot; thyroid nodules or known autonomous (hyperfunctional) thyroid.&#xD;
&#xD;
          -  A reported pathological coronary artery disease.&#xD;
&#xD;
          -  Creatinine &gt; 1.5 mg / dl.&#xD;
&#xD;
          -  During the 2 weeks before surgery, being on medications which are known to interfere&#xD;
             with the ICG (ie anticonvulsants, heparin and haloperidol).&#xD;
&#xD;
          -  Pregnancy or breast feeding period.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marie Nogaret, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle Veys, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophie VanKerckhove, biologist</last_name>
    <role>Study Chair</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe De Neubourg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Danielle Noterman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jules Bordet Insitute</name>
      <address>
        <city>Brussels</city>
        <zip>B-1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>May 6, 2013</study_first_submitted>
  <study_first_submitted_qc>November 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

